Farsight Medical Technology Co. Ltd

Farsight Medical Technology was founded in 2016 by Dr. Ching Pong Mak and Mr. Ye Ding with the mission to undertake innovative drug development in China in areas with un-met clinical needs.

Cypralis and Farsight are jointly exploring the therapeutic potential of cyclophilin inhibitors, the first drug candidate CC-66 is scheduled to enter human trials in Q1/2020 to prevent acute kidney injury after transplantation.

Please contact us to explore opportunities for collaboration or investment.